newsfilter
← Latest News
Business Wire·

Alpine Immune Sciences Reports Third Quarter 2023 Financial Results

-- First clinical data with povetacicept presented at American Society of Nephrology Kidney Week support best-in-class potential and broad pipeline opportunity – -- Company closed an oversubscribed $150 million equity